Increased plasma visfatin concentration is a marker of an atherogenic metabolic profile

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 23, Issue 4, 2013, Pages 330-336

  Filippatos, T D ^a   Tsimihodimos, V ^a   Derdemezis, C S ^a   Gazi, I F ^a   Saougos, V ^a   Mikhailidis, D P ^b   Tselepis, A D ^c   Elisaf, M S ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Apolipoprotein C III; Cardiovascular risk; HDL subclasses; LDL subclasses; Lipoprotein associated phospholipase A2; Paraoxonase; Pre beta1 HDL; Visfatin

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CYTOKINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE, HUMAN; TRIACYLGLYCEROL;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; ATHEROSCLEROSIS; BLOOD; BLOOD PRESSURE; CHI SQUARE DISTRIBUTION; FEMALE; HUMAN; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; UPREGULATION; WAIST CIRCUMFERENCE;

ADULT; AGED; ANALYSIS OF VARIANCE; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BLOOD PRESSURE; C-REACTIVE PROTEIN; CHI-SQUARE DISTRIBUTION; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CYTOKINES; FEMALE; HUMANS; MALE; MIDDLE AGED; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; TRIGLYCERIDES; UP-REGULATION; WAIST CIRCUMFERENCE;

EID: 84875081383     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2011.07.002     Document Type: Article

References (23)

1. Grundy S.M., Cleeman J.I., Merz C.N., Brewer H.B., Clark L.T., Hunninghake D.B., et al. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. J Am Coll Cardiol 2004, 44:720-732.
2. Gazi I.F., Tsimihodimos V., Tselepis A.D., Elisaf M., Mikhailidis D.P. Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles. Expert Opin Biol Ther 2007, 7:53-72.
3. Tellis C.C., Tselepis A.D. The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma. Biochim Biophys Acta 2009, 1791:327-338.
4. Ooi E.M., Barrett P.H., Chan D.C., Watts G.F. Apolipoprotein C-III: understanding an emerging cardiovascular risk factor. Clin Sci (Lond) 2008, 114:611-624.
5. Filippatos T.D., Randeva H.S., Derdemezis C.S., Elisaf M.S., Mikhailidis D.P. Visfatin/PBEF and atherosclerosis-related diseases. Curr Vasc Pharmacol 2010, 8:12-28.
6. Filippatos T.D., Derdemezis C.S., Gazi I.F., Lagos K., Kiortsis D.N., Tselepis A.D., et al. Increased plasma visfatin levels in subjects with the metabolic syndrome. Eur J Clin Invest 2008, 38:71-72.
7. Filippatos T.D., Derdemezis C.S., Kiortsis D.N., Tselepis A.D., Elisaf M.S. Increased plasma levels of visfatin/pre-B cell colony-enhancing factor in obese and overweight patients with metabolic syndrome. J Endocrinol Invest 2007, 30:323-326.
8. Saddi-Rosa P., Oliveira C.S., Giuffrida F.M., Reis A.F. Visfatin, glucose metabolism and vascular disease: a review of evidence. Diabetol Metab Syndr 2010, 2:21.
9. D'Agostino R.B., Grundy S., Sullivan L.M., Wilson P. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001, 286:180-187.
10. Liu S.W., Qiao S.B., Yuan J.S., Liu D.Q. Association of plasma visfatin levels with inflammation, atherosclerosis and acute coronary syndromes (ACS) in humans. Clin Endocrinol (Oxf) 2009, 71:202-207.
11. Kadoglou N.P., Gkontopoulos A., Kapelouzou A., Fotiadis G., Theofilogiannakos E.K., Kottas G., et al. Serum levels of vaspin and visfatin in patients with coronary artery disease-Kozani study. Clin Chim Acta 2011, 412:48-52.
12. Nakou E., Filippatos T.D., Liberopoulos E.N., Tselepis A.D., Kiortsis D.N., Mikhailidis D.P., et al. Effects of sibutramine plus verapamil sustained release/trandolapril combination on blood pressure and metabolic variables in obese hypertensive patients. Expert Opin Pharmacother 2008, 9:1629-1639.
13. Filippatos T.D., Derdemezis C.S., Georgoula M., Kiortsis D.N., Tselepis A.D., Elisaf M.S. Fenofibrate and orlistat, alone or in combination, do not alter plasma visfatin levels in subjects with metabolic syndrome. J Med Sci Res 2007, 2:9-10.
14. Derdemezis C., Filippatos T., Tselepis A., Mikhailidis D., Elisaf M. Effects of ezetimibe, either alone or in combination with atorvastatin, on serum visfatin levels: a pilot study. Expert Opin Pharmacother 2008, 9:1829-1837.
15. Kostapanos M.S., Derdemezis C.S., Filippatos T.D., Milionis H.J., Kiortsis D.N., Tselepis A.D., et al. Effect of rosuvastatin treatment on plasma visfatin levels in patients with primary hyperlipidemia. Eur J Pharmacol 2008, 578:249-252.
16. Sun G., Bishop J., Khalili S., Vasdev S., Gill V., Pace D., et al. Serum visfatin concentrations are positively correlated with serum triacylglycerols and down-regulated by overfeeding in healthy young men. Am J Clin Nutr 2007, 85:399-404.
17. Mirzaei K., Hossein-Nezhad A., Javad Hosseinzadeh-Attar M., Jafari N., Najmafshar A., Mohammadzadeh N., et al. Visfatin genotype may modify the insulin resistance and lipid profile in type 2 diabetes patients. Minerva Endocrinol 2009, 34:273-279.
18. Yang C.C., Deng S.J., Hsu C.C., Liu B.H., Lin E.C., Cheng W.T., et al. Visfatin regulates genes related to lipid metabolism in porcine adipocytes. J Anim Sci 2010, 88:3233-3241.
19. Florentin M., Liberopoulos E.N., Wierzbicki A.S., Mikhailidis D.P. Multiple actions of high-density lipoprotein. Curr Opin Cardiol 2008, 23:370-378.
20. Johansson L.M., Johansson L.E., Ridderstrale M. The visfatin (PBEF1) G-948T gene polymorphism is associated with increased high-density lipoprotein cholesterol in obese subjects. Metabolism 2008, 57:1558-1562.
21. James R.W. A long and winding road: defining the biological role and clinical importance of paraoxonases. Clin Chem Lab Med 2006, 44:1052-1059.
22. Mackness M.I., Mackness B., Durrington P.N. Paraoxonase and coronary heart disease. Atheroscler Suppl 2002, 3:49-55.
23. Gazi I., Lourida E.S., Filippatos T., Tsimihodimos V., Elisaf M., Tselepis A.D. Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clin Chem 2005, 51:2264-2273.